Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines

These observations support a role for the combination of a histone deacetylase inhibitor and a TKI in the treatment of NSCLCs.